These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11956450)

  • 21. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up].
    Martínez Sarmiento M; Cuñat Albert E; López Alcina E; Pontones Moreno JL; Sanz Chinesta S; Jiménez Cruz JF
    Actas Urol Esp; 1997 Feb; 21(2):105-10. PubMed ID: 9214205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B; Kann PH
    Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
    Kearney MC; Bingham J; Bergland R; Meade-D'Alisera P; Puchner PJ
    J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finasteride treatment and neuroactive steroid formation.
    Dusková M; Hill M; Hanus M; Matousková M; Stárka L
    Prague Med Rep; 2009; 110(3):222-30. PubMed ID: 19655698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
    Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
    J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The long-term treatment of patients with benign prostatic hyperplasia using Proscar].
    Lopatkin NA; Roilans PJ; Stoner E
    Urol Nefrol (Mosk); 1996; (1):2-4. PubMed ID: 8659035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
    Ravish IR; Nerli RB; Amarkhed SS
    Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study.
    Tollin SR; Rosen HN; Zurowski K; Saltzman B; Zeind AJ; Berg S; Greenspan SL
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1031-4. PubMed ID: 8772571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of finasteride on prostate tissue composition.
    Marks LS; Partin AW; Dorey FJ; Gormley GJ; Epstein JI; Garris JB; Macairan ML; Shery ED; Santos PB; Stoner E; deKernion JB
    Urology; 1999 Mar; 53(3):574-80. PubMed ID: 10096387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis.
    Lovell DJ; Glass D; Ranz J; Kramer S; Huang B; Sierra RI; Henderson CJ; Passo M; Graham B; Bowyer S; Higgins G; Rennebohm R; Schikler KN; Giannini E
    Arthritis Rheum; 2006 Jul; 54(7):2235-42. PubMed ID: 16802360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.
    Donohue JF; Hayne D; Karnik U; Thomas DR; Foster MC
    BJU Int; 2005 Dec; 96(9):1319-22. PubMed ID: 16287453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.
    Willemsen RH; Arends NJ; Bakker-van Waarde WM; Jansen M; van Mil EG; Mulder J; Odink RJ; Reeser M; Rongen-Westerlaken C; Stokvis-Brantsma WH; Waelkens JJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
    Roberts JL; Fiedler V; Imperato-McGinley J; Whiting D; Olsen E; Shupack J; Stough D; DeVillez R; Rietschel R; Savin R; Bergfeld W; Swinehart J; Funicella T; Hordinsky M; Lowe N; Katz I; Lucky A; Drake L; Price VH; Weiss D; Whitmore E; Millikan L; Muller S; Gencheff C
    J Am Acad Dermatol; 1999 Oct; 41(4):555-63. PubMed ID: 10495375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.